Lepu Medical Technology (Beijing) Co (300003) Fair Value & Analysis
Healthcare · CN · Market cap 21.8B CNY
Fair value as of: Jul 7, 2026
From 26 valuation models · updated 34 days ago
Share price +6.9% over the past month.
A solid business, but screening 13% overvalued on our models.
What matters now
- Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from ¥8.61 (bear) to ¥14.35 (bull), base ¥11.48. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 65/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 7, 2026.
How to read this chart
60‑month range ¥8.86 – ¥31.72 · fair‑value band ¥8.61 – ¥14.35 · the ¥13.14 price screens above the ¥11.48 fair value. Dashed = 300-day average. As of Jul 7, 2026.
Analysis
Lepu Medical Technology (Beijing) Co (300003) currently trades at ¥13.14, while our model-based Fair Value estimate is ¥11.48, implying the stock looks roughly 12.6% overvalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Lepu Medical Technology (Beijing) Co generated revenue of 6.4B CNY at a net margin of 12.9%. Revenue declined 3.7% year over year. It earns a return on equity of 4.9%. Net debt stands at 460M CNY. Fundamentals as of Jul 7, 2026
Our scenario range runs from ¥8.61 (bear case) to ¥14.35 (bull case); at ¥13.14, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -13%, 300003 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥14.50) versus Asset-Based (¥5.86). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Lepu Medical Technology (Beijing) Co., Ltd., together with its subsidiaries, engages in the research, development, and manufacturing of cardiac interventional medical devices in China and internationally. The company operates through three segments: Medical Devices; Pharmaceuticals; and Medical Services and Health Management.
Full company description
Lepu Medical Technology (Beijing) Co., Ltd., together with its subsidiaries, engages in the research, development, and manufacturing of cardiac interventional medical devices in China and internationally. The company operates through three segments: Medical Devices; Pharmaceuticals; and Medical Services and Health Management. It offers medical devices, including cardiovascular devices, in vitro diagnostics, surgical instruments, peripheral blood vessels, blood purification, ultrasound imaging, and orthopedic products; pharmaceutical products for cardiovascular, digestive, central nervous, and respiratory systems, as well as antimicrobial, nutrition, traditional Chinese medicine, lowering blood sugar, and health food; and medical services and health management, such as medical services, AI, home appliances, and medical aesthetics and daily chemical products. The company is also involved in investment activities; trading; technological development; and pension services. It exports its products. The company was founded in 1999 and is based in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Lepu Medical Technology (Beijing) Co reported revenue of ¥6.5B in FY2025 versus ¥10.7B in FY2021, a compound −11.7%/yr. Reported net income was ¥962M in FY2025, compounding −13.5%/yr from FY2021.
300003 screens 13% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Lepu Medical Technology (Beijing) Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lepu Medical Technology (Beijing) Co (300003) overvalued or undervalued?
What is the fair value of 300003?
What is the quality score of 300003?
What is the revenue of Lepu Medical Technology (Beijing) Co (300003)?
What is the net profit margin of 300003?
Does Lepu Medical Technology (Beijing) Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Lepu Medical Technology (Beijing) Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.